“Morgan Stanley Predicts up to ~230% Surge for These 2 ‘Strong Buy’ Stocks”
August 12, 2024
“CervoMed (CRVO)
The first Morgan Stanley pick we’ll look at is CervoMed, a clinical-stage medical research firm specializing in neurodegenerative diseases and conditions… Overall, the analyst expects positive clinical results and rates CRVO an Overweight (i.e., Buy). His $35 price target indicates a robust ~230% upside potential over the next 12 months…
Viking Therapeutics (VKTX)
Next under the Morgan Stanley microscope is Viking Therapeutics, a clinical-stage biopharmaceutical researcher dedicated to developing treatments for metabolic and endocrine disorders… All in all, there are 10 positive reviews on record for VKTX, supporting the Strong Buy consensus rating. The shares are currently trading for $53.05 and the stock has a 112% upside for the coming year, based on its average price target of $112.63…”
https://finance.yahoo.com/news/morgan-stanley-predicts-230-surge-130315551.html
See the bold. Basically this will be dealing with the transgender community. Any damage caused by hormone blockers or endocrine disruptions — My guess is this’ll be a possible “solution.” If not directly related its certainly leaning in that direction. Problem, reaction, solution. This is probably going to be a profitable company. Is it ethical? Probably not.